Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies.
Beurskens
Frank J
FJ
Ruuls
Sigrid R
SR
Engelberts
Patrick J
PJ
Vink
Tom
T
Mackus
Wendy J
WJ
van de Winkel
Jan G J
JG
Parren
Paul W H I
PW
D000818:Animals; D000911:Antibodies, Monoclonal / Q000235:genetics / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology*; D058846:Antibodies, Monoclonal, Murine-Derived; D000920:Antibody-Dependent Cell Cytotoxicity / Q000235:genetics / Q000276:immunology*; D018951:Antigens, CD20 / Q000276:immunology* / Q000378:metabolism; D000970:Antineoplastic Agents / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology*; D003167:Complement Activation / Q000187:drug effects* / Q000235:genetics / Q000276:immunology; D015922:Complement C1q / Q000276:immunology / Q000378:metabolism; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006801:Humans; D007127:Immunoglobulin Constant Regions / Q000235:genetics / Q000276:immunology; D008212:Lymphocyte Depletion / Q000379:methods*; D020125:Mutation, Missense; D011485:Protein Binding / Q000235:genetics / Q000276:immunology; D017452:Receptors, IgG / Q000235:genetics / Q000276:immunology; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; C517507:FcgammaRIIIA protein, mouse; D007127:Immunoglobulin Constant Regions; D017452:Receptors, IgG; D000069283:Rituximab; D015922:Complement C1q